|
| Wednesday, October 4, 2017 |
|
|
Eisai and Biotoscana Sign Exclusive Licensing Agreement for Latin America |
| Eisai Co., Ltd. announced today that its U.S. subsidiary, Eisai Inc., has signed an exclusive licensing agreement with Grupo Biotoscana for Eisai's oncology and neurology products in Latin America. more info >> |
|
| Tuesday, October 3, 2017 |
|
|
Sato Pharmaceutical and Eisai to Co-Promote New Oral Antifungal Agent Containing Active Ingredient Fosravuconazole in Japan |
| Sato Pharmaceutical Co., Ltd., Eisai Co., Ltd., and Seren Pharmaceuticals Inc. announced today that Sato Pharma and Eisai will co-promote a new triazole class oral antifungal agent (development code: BFE1224, "the agent") containing the active ingredient fosravuconazole L-lysine ethanolate ("fosravuconazole") in Japan, based on an agreement between the three companies. more info >> |
|
| Friday, September 29, 2017 |
|
|
Eisai Presents Results of Phase Iii Trial of Lenvima (Lenvatinib) in Unresectable Hepatocellular Carcinoma in Oral Session at 20th CSCO Annual Meeting |
| In the subpopulation analysis, lenvatinib demonstrated efficacy based on extension of Overall Survival (OS) compared to sorafenib (nominal P = 0.026), with improvements also observed in Progression Free Survival (PFS), Time to Progression (TTP) and Objective Response Rate (ORR) (see table below). more info >> |
|
| Wednesday, September 27, 2017 |
|
|
Eisai: Application for Additional Indication of Lenvima for Hepatocellular Carcinoma Accepted for Review by U.S. FDA |
| This application is based on the results of the REFLECT study (Study 304), a multicenter, open-label, randomized, global Phase III trial comparing the efficacy and safety of Lenvima versus sorafenib, a standard treatment for HCC, as a first-line treatment for patients with unresectable HCC. more info >> |
|
| Friday, September 22, 2017 |
|
|
エーザイ: プロトンポンプ阻害剤「パリエット(R)錠5mg、錠10mg」 日本でプロトンポンプ阻害剤抵抗性の逆流性食道炎に対する維持療法の用法・用量追加の承認を取得 |
| エーザイ株式会社とエーザイの消化器事業子会社であるEAファーマ株式会社は、本日、エーザイが、日本において、プロトンポンプ阻害剤 「パリエット(R)錠5mg、錠10mg」（一般名 ：ラベプラゾールナトリウム）について、プロトンポンプ阻害剤抵抗性 逆流性食道炎（プロトンポンプ阻害剤の1日1回投与による従来の治療で効果不十分な逆流性食道炎）に対する維持療法に関して、ラベプラゾールナトリウムとして1回10mg 1日2回投与の用法・用量追加の承認を取得したことをお知らせします。 more info >> |
|
|
エーザイ初の抗体薬物複合体MORAb-202に関する最新の非臨床試験データを第8回World ADC年次総会において発表 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、当社の研究開発会社であるモルフォテック・インクが創製したエーザイ初の抗体薬物複合体（Antibody-Drug Conjugate：ADC）である MORAb-202 に関する最新非臨床試験データを、「第 8 回 World ADC 年次総会」において発表しましたので、お知らせします。 more info >> |
|
|
Eisai: Additional Dosage and Administration of Proton Pump Inhibitor Pariet 5 mg Tablets, 10 mg Tablets Approved in Japan for Maintenance Therapy of Proton Pump Inhibitor Resistant Reflux Esophagitis |
| Eisai Co., Ltd. and Eisai's subsidiary for gastrointestinal disease area EA Pharma Co., Ltd. announced today that Eisai has obtained the approval of additional dosage and administration in Japan of the proton pump inhibitor Pariet 5 mg Tablets and 10 mg Tablets to administer 10 mg of rabeprazole sodium per dose twice-daily for the maintenance therapy of proton pump inhibitor-resistant reflux esophagitis. more info >> |
|
|
Eisai Presents Latest Non-Clinical Data on Its First Antibody-Drug Conjugate MORAb-202 at 8th Annual World ADC |
| Eisai Co., Ltd. announced today that the latest non-clinical data on MORAb-202, Eisai's first antibody-drug conjugate (ADC) developed by its research subsidiary Morphotek, Inc., was presented at the 8th Annual World ADC. more info >> |
|
| Tuesday, September 19, 2017 |
|
|
エーザイ、「レンビマ(R)」（レンバチニブ）の全身化学療法歴のない切除不能な肝細胞がんを対象とした臨床第III相試験結果を第11回国際肝癌学会年次総会にて発表 |
| エーザイ株式会社は、このたび、自社創製の抗がん剤レンバチニブメシル酸塩（一般名、製品名：「レンビマ(R)」「Kisplyx(R)」、以下 レンバチニブ）に関する全身化学療法歴のない切除不能な肝細胞がんにおけるソラフェニブを対照薬とした臨床第III相試験（REFLECT/304 試験）について 1、B 型肝炎ウイルス由来の肝細胞がん患者様の部分集団解析結果を、韓国ソウルで開催された第 11 回国際肝癌学会年次総会にて初めて発表しましたのでお知らせします。 more info >> |
|
|
Eisai Presents Results of Phase Iii Clinical Study of Lenvima (Lenvatinib) in Unresectable Hepatocellular Carcinoma at 11th ILCA Annual Conference |
| In the total population analysis of this study, the treatment effect of lenvatinib for all patients on the primary endpoint of Overall Survival (OS) was demonstrated by statistical confirmation of non-inferiority to sorafenib. more info >> |
|
|
|
|
